Last updated: 11/08/2018 17:18:04
Study to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease
Trial description: The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of participants with death (both on and off treatment) due to any cause, time up to or on the pre-determined common end date
Timeframe: From the date of randomization until date of death due to any cause (average of 2 study years)
Secondary outcomes:
Decline in forced expiratory volume in 1 second (FEV1)
Timeframe: From start date of IP until IP stop date + 1 (assessed up to 4 years)
Number of participants with first on-treatment cardiovascular (CV) composite events occured on or before common end date
Timeframe: From the start of IP to first on treatment CV event till 7 days after the last dose of IP (average of 2 study years)
Interventions:
Drug: fluticasone furoate/vilanterol
Drug: fluticasone furoate
Drug: vilanterol
Other: Placebo
Enrollment:
16568
Observational study model:
Not applicable
Primary completion date:
2015-15-07
Time perspective:
Not applicable
Clinical publications:
Jørgen Vestbo, Julie A Anderson, Robert D Brook, Peter MA Calverley, Bartolome R Celli, Courtney Crim, Fernando Martinez, Julie Yates, David E Newby. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk. Lancet. 2016;387(10030):1789-1878
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
fluticasone furoate, fluticasone furoate/vilanterol, vilanterol
Collaborators
Not applicable
Study date(s)
January 2011 to July 2015
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
40 - 80 years
Accepts healthy volunteers
No
- Type of subject: outpatient.
- Informed consent: Subjects must give their signed and dated written informed consent to participate.
- Pregnancy: Women who are pregnant or lactating.
- Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they also have a current diagnosis of COPD).
Inclusion and exclusion criteria
Inclusion criteria:
- Type of subject: outpatient.
- Informed consent: Subjects must give their signed and dated written informed consent to participate.
- Gender: Male or female. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception.
- Age: >=40 and <=80 years of age at Screening (Visit 1).
- Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.
- Airflow Obstruction: Subjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of <=0.70 at Screening (Visit 1). Subjects with a measured post-albuterol/salbutamol FEV1 >=50 and <=70% of predicted normal values calculated using NHANES III reference equations [Hankinson, 1999; Hankinson, 2010] at Screening (Visit 1). Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated.
- Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1)
- Cardiovascular disease: For patients >= 40 years of age: any one of the following: Established (i.e. by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e. by clinical signs or imaging studies) peripheral vascular disease (PVD) Previous stroke Previous MI Diabetes mellitus with target organ disease OR For patients >=60 years of age: any 2 of the following: Being treated for hypercholesterolemia Being treated for hypertension Being treated for diabetes mellitus Being treated for peripheral vascular disease
Exclusion criteria:
- Pregnancy: Women who are pregnant or lactating.
- Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they also have a current diagnosis of COPD).
- alpha 1-antitrypsin deficiency: Subjects with known alpha-1 antitrypsin deficiency as the underlying cause of COPD.
- Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases.
- Lung resection or transplantation: Subjects with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant.
- A moderate/severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable).
- Current severe heart failure (New York Heart Association class IV). Subjects will also be excluded if they have a known ejection fraction of <30% or if they have an implantable cardioverter defibrillator (ICD).
- Other diseases/abnormalities: Any life-threatening condition with life expectancy <3 years, other than vascular disease or COPD, that might prevent the subject from completing the study.
- End stage chronic renal disease: Subjects will be excluded if on renal replacement therapy (hemodialysis or peritoneal).
- Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). In addition, patients with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject’s participation will also be excluded.
- Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years.
- Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e. <=12 hours per day) is not exclusionary.
- Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study or the potential compliance to study procedures.
- Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
- Additional medication: Use of the following medications within the following time intervals prior to Visit 1 or during the study (unless otherwise specified): Medication No use within the following time intervals prior to Screening or thereafter at any time during the study (unless otherwise specified) Inhaled Long acting beta-agonists (LABA) 48 hours ICS/LABA combination products 48 hours Inhaled corticosteroids 48 hours Tiotropium 1 week Systemic, Oral, parenteral, intra-articular corticosteroids 30 days (oral and systemic corticosteroids may be used to treat COPD exacerbations during the study) Cytochrome P450 3A4 strong inhibitors including but not limited to antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole anti-fungals (e.g. Ketaconazole, Itraconazole); Clarithromycin, Telithromycin, Amiodarone, and Nefazodone 6 weeks Grapefruit is allowed up to Visit 1, then limited to no more than one glass of grapefruit juice (250 mL/ 8 ounces) or one grapefruit per day Any other investigational drug 30 days or 5 half lives whichever is longer.
Trial location(s)
Location
GSK Investigational Site
Elizabeth, New Jersey, United States, 07201
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Anaheim, California, United States, 92801
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Decatur, Georgia, United States, 30033
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10001
Status
Study Complete
Location
GSK Investigational Site
North Dartmouth, Massachusetts, United States, 02747
Status
Study Complete
Location
GSK Investigational Site
Rosario, Santa Fe, Argentina, S2000CVD
Status
Study Complete
Location
GSK Investigational Site
Rock Hill, South Carolina, United States, 29732
Status
Study Complete
Location
GSK Investigational Site
Sarasota, Florida, United States, 34239
Status
Study Complete
Location
GSK Investigational Site
Bronxville, New York, United States, 10708
Status
Study Complete
Location
GSK Investigational Site
Shelby, North Carolina, United States, 28152
Status
Study Complete
Location
GSK Investigational Site
Reinfeld, Schleswig-Holstein, Germany, 23858
Status
Study Complete
Location
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53119
Status
Study Complete
Location
GSK Investigational Site
San Jose, California, United States, 95116
Status
Study Complete
Location
GSK Investigational Site
Uniontown, Pennsylvania, United States, 15401
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10019
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Great Falls, Montana, United States, 59405
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1028AAP
Status
Study Complete
Location
GSK Investigational Site
Calhoun, Georgia, United States, 30701
Status
Study Complete
Location
GSK Investigational Site
Lincoln, Nebraska, United States, 02865
Status
Study Complete
Location
GSK Investigational Site
Torrance/California, California, United States, 90505
Status
Study Complete
Location
GSK Investigational Site
Lewisville, Texas, United States, 75067
Status
Study Complete
Location
GSK Investigational Site
Pinellas Park, Florida, United States, 33781
Status
Study Complete
Location
GSK Investigational Site
Pasadena, California, United States, 91105
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45242
Status
Study Complete
Location
GSK Investigational Site
Elkton, Maryland, United States, 21921
Status
Study Complete
Location
GSK Investigational Site
Metairie, Louisiana, United States, 70006
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10038
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Evergreen Park, Illinois, United States, 60805
Status
Study Complete
Location
GSK Investigational Site
Pensacola, Florida, United States, 32503
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84102
Status
Study Complete
Location
GSK Investigational Site
Bay Pines, Florida, United States, 33744
Status
Study Complete
Location
GSK Investigational Site
South Miami, Florida, United States, 33143
Status
Study Complete
Location
GSK Investigational Site
Peoria, Illinois, United States, 61602
Status
Study Complete
Location
GSK Investigational Site
Fort Worth, Texas, United States, 76104
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Coeur d'Alene, Idaho, United States, 90212
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Tucuman, Tucumán, Argentina, 4000
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Fleetwood, Pennsylvania, United States, 19522
Status
Study Complete
Location
GSK Investigational Site
Salem, New Jersey, United States, 08079
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Clearwater, Florida, United States, 33765-2616
Status
Study Complete
Location
GSK Investigational Site
Stubicke toplice, Croatia, 49244
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bellevue, Nebraska, United States, 68123-4303
Status
Study Complete
Location
GSK Investigational Site
Neuss, Nordrhein-Westfalen, Germany, 41462
Status
Study Complete
Location
GSK Investigational Site
Meyerspark, Gauteng, South Africa, 0184
Status
Study Complete
Location
GSK Investigational Site
Simi Valley, California, United States, 93065
Status
Study Complete
Location
GSK Investigational Site
Rochester, New York, United States, 14618
Status
Study Complete
Location
GSK Investigational Site
Brockton, Massachusetts, United States, 02301
Status
Study Complete
Location
GSK Investigational Site
Pelzer, South Carolina, United States, 29669
Status
Study Complete
Location
GSK Investigational Site
Abingdon, Virginia, United States, 24210
Status
Study Complete
Location
GSK Investigational Site
Biddeford, Maine, United States, 04005
Status
Study Complete
Location
GSK Investigational Site
Huntsville, Alabama, United States, 35801
Status
Study Complete
Location
GSK Investigational Site
Wheatridge, Colorado, United States, 80033
Status
Study Complete
Location
GSK Investigational Site
Loma Linda, California, United States, 92357
Status
Study Complete
Location
GSK Investigational Site
Cipoletti, Rio Negro, Río Negro, Argentina, R8324CVE
Status
Study Complete
Location
GSK Investigational Site
Montgomery/Alabama, Alabama, United States, 36106
Status
Study Complete
Location
GSK Investigational Site
Champaign, Illinois, United States, 61820
Status
Study Complete
Location
GSK Investigational Site
Edmonton, Alberta, Canada, T5J 3S9
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Los Angeles, California, United States, 90033
Status
Study Complete
Location
GSK Investigational Site
San Isidro, Buenos Aires, Argentina, B1642DCD
Status
Study Complete
Location
GSK Investigational Site
Morgantown, West Virginia, United States, 26505
Status
Study Complete
Location
GSK Investigational Site
Columbia, Maryland, United States, 21044
Status
Study Complete
Location
GSK Investigational Site
Corsicana, Texas, United States, 75110
Status
Study Complete
Location
GSK Investigational Site
Corpus Christi, Texas, United States, 78405
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Quincy, Illinois, United States, 62301
Status
Study Complete
Location
GSK Investigational Site
Greenwood, South Carolina, United States, 29646
Status
Study Complete
Location
GSK Investigational Site
Lehigh Acres, Florida, United States, 33971
Status
Study Complete
Location
GSK Investigational Site
Oak Lawn, Illinois, United States, 60453
Status
Study Complete
Location
GSK Investigational Site
Modesto, California, United States, 95350
Status
Terminated/Withdrawn
Location
GSK Investigational Site
New York, New York, United States, 10004
Status
Study Complete
Location
GSK Investigational Site
Greer, South Carolina, United States, 29650
Status
Study Complete
Location
GSK Investigational Site
Galveston, Texas, United States, 77555
Status
Study Complete
Location
GSK Investigational Site
Saint Petersburg, Florida, United States, 33713
Status
Study Complete
Location
GSK Investigational Site
Lincoln, Nebraska, United States, 68506
Status
Study Complete
Location
GSK Investigational Site
Adrogue, Buenos Aires, Argentina, B1846DSK
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32209
Status
Study Complete
Location
GSK Investigational Site
Sacramento, California, United States, 95821
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23229
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35209
Status
Study Complete
Location
GSK Investigational Site
Bergisch Gladbach, Nordrhein-Westfalen, Germany, 51429
Status
Study Complete
Location
GSK Investigational Site
Kissimmee, Florida, United States, 34741
Status
Study Complete
Location
GSK Investigational Site
Dresden, Sachsen, Germany, 01067
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Antonio, Texas, United States, 78212
Status
Study Complete
Location
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
Status
Study Complete
Location
GSK Investigational Site
Fremont, Nebraska, United States, 68025
Status
Study Complete
Location
GSK Investigational Site
Nueve de Julio, Buenos Aires, Argentina, B6500BWQ
Status
Study Complete
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 4E1
Status
Study Complete
Location
GSK Investigational Site
Alabang, Muntinlupa City, Philippines, 1780
Status
Study Complete
Location
GSK Investigational Site
Towson, Maryland, United States, 21204
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Maumee, Ohio, United States, 43537-9402
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97219
Status
Study Complete
Location
GSK Investigational Site
Franklin, Indiana, United States, 46131
Status
Study Complete
Location
GSK Investigational Site
Middelburg, Mpumalanga, South Africa, 1055
Status
Study Complete
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28209
Status
Study Complete
Location
GSK Investigational Site
Huntsville, Alabama, United States, 35816
Status
Study Complete
Location
GSK Investigational Site
Milton Keynes, United Kingdom, MK6 5LD
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Suwanee, Georgia, United States, 30024
Status
Study Complete
Location
GSK Investigational Site
Gracanica, Bosnia and Herzegovina, 75320
Status
Study Complete
Location
GSK Investigational Site
Sugarland, Texas, United States, 77478
Status
Study Complete
Location
GSK Investigational Site
Riverside, California, United States, 92506
Status
Study Complete
Location
GSK Investigational Site
Margate, New Jersey, United States, 08402
Status
Study Complete
Location
GSK Investigational Site
Montgomery, Alabama, United States, 36109
Status
Study Complete
Location
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
Status
Study Complete
Location
GSK Investigational Site
Monterey Park, California, United States, 91754
Status
Study Complete
Location
GSK Investigational Site
Sidcup, Kent, United Kingdom, DA14 6LT
Status
Study Complete
Location
GSK Investigational Site
Hialeah, Florida, United States, 33016
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Diego, California, United States, 92108
Status
Study Complete
Location
GSK Investigational Site
Billings, Montana, United States, 59101
Status
Study Complete
Location
GSK Investigational Site
Celebration, Florida, United States, 34747
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10009
Status
Study Complete
Location
GSK Investigational Site
Lakewood, California, United States, 90712
Status
Study Complete
Location
GSK Investigational Site
Council Bluffs, Iowa, United States, 51503
Status
Study Complete
Location
GSK Investigational Site
Sarajevo, Bosnia and Herzegovina, 71000
Status
Study Complete
Location
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, C1425AGC
Status
Study Complete
Location
GSK Investigational Site
Columbus,, Ohio, United States, 43214
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Calabash, North Carolina, United States, 28467
Status
Study Complete
Location
GSK Investigational Site
Midlothian, Virginia, United States, 23114
Status
Study Complete
Location
GSK Investigational Site
Waterbury, Connecticut, United States, 06708
Status
Study Complete
Location
GSK Investigational Site
Bangor, Maine, United States, 04401
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Fort Lauderdale, Florida, United States, 33316
Status
Study Complete
Location
GSK Investigational Site
Travnik, Bosnia and Herzegovina, 72270
Status
Study Complete
Location
GSK Investigational Site
Fort Collins, Colorado, United States, 80538
Status
Study Complete
Location
GSK Investigational Site
Quilmes, Buenos Aires, Argentina, 1878
Status
Study Complete
Location
GSK Investigational Site
Ostrowiec Swietokrzyski, Poland, 27-400
Status
Study Complete
Location
GSK Investigational Site
Suwon, Gyeonggi-do, South Korea, 442-723
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Santiago del Estero, Santiago Del Estero, Argentina
Status
Study Complete
Location
GSK Investigational Site
Fort Collins, Colorado, United States, 80528
Status
Study Complete
Location
GSK Investigational Site
Oakland Park, Florida, United States, 33309
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19152
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15243
Status
Study Complete
Location
GSK Investigational Site
Encinitas, California, United States, 92024
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45220
Status
Study Complete
Location
GSK Investigational Site
Zephyrhills, Florida, United States, 33540
Status
Study Complete
Location
GSK Investigational Site
Cleveland, Ohio, United States, 44106
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ann Arbor, Michigan, United States, 48106
Status
Study Complete
Location
GSK Investigational Site
Scotdale, Pennsylvania, United States, 15683
Status
Study Complete
Location
GSK Investigational Site
Lafayette, Louisiana, United States, 70508
Status
Study Complete
Location
GSK Investigational Site
Springfield, Oregon, United States, 97477
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78233
Status
Study Complete
Location
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53123
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99202
Status
Study Complete
Location
GSK Investigational Site
Trebinje, Bosnia and Herzegovina, 89101
Status
Study Complete
Location
GSK Investigational Site
Anderson, South Carolina, United States, 29621
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63141
Status
Study Complete
Location
GSK Investigational Site
Toledo, Ohio, United States, 43614-5809
Status
Study Complete
Location
GSK Investigational Site
San Miguel de Tucuman, Argentina, 4000
Status
Study Complete
Location
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44787
Status
Study Complete
Location
GSK Investigational Site
Clearwater, Florida, United States, 33756
Status
Study Complete
Location
GSK Investigational Site
Edina, Minnesota, United States, 55435
Status
Study Complete
Location
GSK Investigational Site
Jersey Shore, Pennsylvania, United States, 17740
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Montclair, California, United States, 91763
Status
Study Complete
Location
GSK Investigational Site
Weissenhorn, Bayern, Germany, 89264
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Manhattan, New York, United States, 10029
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ettlingen, Baden-Wuerttemberg, Germany, 76275
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55407
Status
Study Complete
Location
GSK Investigational Site
Bakersfield, California, United States, 93301
Status
Study Complete
Location
GSK Investigational Site
Colorado Springs, Colorado, United States, 80910
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92120
Status
Study Complete
Location
GSK Investigational Site
Mostar, Bosnia and Herzegovina, 88000
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Langhorne, Pennsylvania, United States, 19047
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Washington, District of Columbia, United States, 20422
Status
Study Complete
Location
GSK Investigational Site
Woodbury, Minnesota, United States, 55125
Status
Study Complete
Location
GSK Investigational Site
Bell Vernon, Pennsylvania, United States, 15012
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Mission Hills, California, United States, 91345
Status
Study Complete
Location
GSK Investigational Site
West Jordan, Utah, United States, 84088
Status
Study Complete
Location
GSK Investigational Site
St. Petersburg, Florida, United States, 33709
Status
Study Complete
Location
GSK Investigational Site
Bensalem, Pennsylvania, United States, 19020
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Wardenburg, Niedersachsen, Germany, 26203
Status
Study Complete
Location
GSK Investigational Site
Greenville, North Carolina, United States, 27858
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Melbourne, Victoria, Australia, 3004
Status
Terminated/Withdrawn
Location
GSK Investigational Site
East Providence, Rhode Island, United States, 02914
Status
Study Complete
Location
GSK Investigational Site
Columbia, South Carolina, United States, 29201
Status
Study Complete
Location
GSK Investigational Site
Mae Rim, Chiang Mai, Thailand, 50180
Status
Terminated/Withdrawn
Location
GSK Investigational Site
St. Paul, Minnesota, United States, 55130
Status
Study Complete
Location
GSK Investigational Site
Greer, South Carolina, United States, 29651
Status
Study Complete
Location
GSK Investigational Site
Lancaster, California, United States, 93534
Status
Study Complete
Location
GSK Investigational Site
Elizabeth, New Jersey, United States, 07202
Status
Study Complete
Location
GSK Investigational Site
Greenfield, Indiana, United States, 46140
Status
Study Complete
Location
GSK Investigational Site
Indian Land, South Carolina, United States, 29707
Status
Study Complete
Location
GSK Investigational Site
Hawesville, Kentucky, United States, 42348
Status
Study Complete
Location
GSK Investigational Site
Harsewinkel, Nordrhein-Westfalen, Germany, 33428
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Dundee, KwaZulu- Natal, South Africa, 3000
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35216
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21201
Status
Study Complete
Location
GSK Investigational Site
Bedford, Bedfordshire, United Kingdom, MK404AW
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greensboro, North Carolina, United States, 27405
Status
Study Complete
Location
GSK Investigational Site
Birmingham,, Alabama, United States, 35242
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10028
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23220
Status
Study Complete
Location
GSK Investigational Site
Ostrava - Belsky les, Czech Republic, 700 30
Status
Study Complete
Location
GSK Investigational Site
Sepulveda, California, United States, 91343
Status
Study Complete
Location
GSK Investigational Site
Lexington, North Carolina, United States, 27295
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ventura, California, United States, 93003
Status
Study Complete
Location
GSK Investigational Site
Wilmington, North Carolina, United States, 28401
Status
Study Complete
Location
GSK Investigational Site
Bedford, Bedfordshire, United Kingdom, MK42 9DJ
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Detroit, Michigan, United States, 48221
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1426ABP
Status
Study Complete
Location
GSK Investigational Site
Morgantown, West Virginia, United States, 28506
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Gradiska, Bosnia and Herzegovina, 78400
Status
Study Complete
Location
GSK Investigational Site
Mirabel, Québec, Canada, J7J 2K8
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Chattanooga, Tennessee, United States, 37404
Status
Study Complete
Location
GSK Investigational Site
Alexandria, Virginia, United States, 22304
Status
Study Complete
Location
GSK Investigational Site
Salisbury, North Carolina, United States, 28144
Status
Study Complete
Location
GSK Investigational Site
Wonju-si, Kanwon-do, South Korea, 220-701
Status
Study Complete
Location
GSK Investigational Site
Lampung Selatan, Indonesia, 35373
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bijeljina, Bosnia and Herzegovina, 76300
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Traverse City, Michigan, United States, 49684
Status
Study Complete
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85018
Status
Study Complete
Location
GSK Investigational Site
Houston, Texas, United States, 77099
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hialeah, Florida, United States, 33013
Status
Study Complete
Location
GSK Investigational Site
Winter Park, Florida, United States, 32789
Status
Study Complete
Location
GSK Investigational Site
Kralupy nad Vltavou, Czech Republic, 278 01
Status
Study Complete
Location
GSK Investigational Site
Buckley, Michigan, United States, 49620
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99204
Status
Study Complete
Location
GSK Investigational Site
Buckshaw Village, Chorley, Lancashire, United Kingdom, PR7 7NA
Status
Study Complete
Location
GSK Investigational Site
Florence, South Carolina, United States, 29501
Status
Study Complete
Location
GSK Investigational Site
Lawrenceville, Georgia, United States, 30046
Status
Study Complete
Location
GSK Investigational Site
Erie, Pennsylvania, United States, 16508
Status
Study Complete
Location
GSK Investigational Site
Doylestown, Pennsylvania, United States, 18901
Status
Study Complete
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40202
Status
Study Complete
Location
GSK Investigational Site
Zerbst, Sachsen-Anhalt, Germany, 39261
Status
Study Complete
Location
GSK Investigational Site
San Marino, California, United States, 91108
Status
Study Complete
Location
GSK Investigational Site
Pordenone, Friuli-Venezia-Giulia, Italy, 33170
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Jindrichuv Hradec, Czech Republic, 377 01
Status
Study Complete
Location
GSK Investigational Site
Tuscumbia, Alabama, United States, 35674
Status
Study Complete
Location
GSK Investigational Site
West Des Moines, Iowa, United States, 50265
Status
Study Complete
Location
GSK Investigational Site
Scottsdale, Arizona, United States, 85258
Status
Study Complete
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29407
Status
Study Complete
Location
GSK Investigational Site
Clearwater, Florida, United States, 33755
Status
Study Complete
Location
GSK Investigational Site
Downington, Pennsylvania, United States, 19335
Status
Study Complete
Location
GSK Investigational Site
Miami, Florida, United States, 33135
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Brooklyn, New York, United States, 11215
Status
Study Complete
Location
GSK Investigational Site
Clairton, Pennsylvania, United States, 15025
Status
Study Complete
Location
GSK Investigational Site
Shelbyville, Tennessee, United States, 37160
Status
Study Complete
Location
GSK Investigational Site
La Plata, Buenos Aires, Argentina, B1900AXI
Status
Study Complete
Location
GSK Investigational Site
San Nicolas, Buenos Aires, Argentina, B2900IIC
Status
Study Complete
Location
GSK Investigational Site
Formosa, Formosa, Argentina, 3600
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
Status
Study Complete
Location
GSK Investigational Site
Rolling Hills Estates, California, United States, 90274
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Denver, Colorado, United States, 80206
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 91910
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Andalusia, Alabama, United States, 36420
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55417
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autnónoma de Buenos Aires, Buenos Aires, Argentina, C1186ACB
Status
Study Complete
Location
GSK Investigational Site
Daytona Beach, Florida, United States, 32117
Status
Study Complete
Location
GSK Investigational Site
Miamisburg, Ohio, United States, 45342
Status
Study Complete
Location
GSK Investigational Site
Grand Blanc, Michigan, United States, 48439
Status
Study Complete
Location
GSK Investigational Site
Leesburg, Florida, United States, 34748
Status
Study Complete
Location
GSK Investigational Site
Usti nad Labem - Klise, Czech Republic, 400 01
Status
Study Complete
Location
GSK Investigational Site
Uijeongbu, Gyeonggi-do, South Korea, 480-717
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78258
Status
Study Complete
Location
GSK Investigational Site
Rochester, Minnesota, United States, 55905
Status
Study Complete
Location
GSK Investigational Site
Nashville, Tennessee, United States, 37215
Status
Study Complete
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500691
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23235
Status
Study Complete
Location
GSK Investigational Site
Linden, New Jersey, United States, 07036
Status
Study Complete
Location
GSK Investigational Site
Kansas City, Missouri, United States, 64128
Status
Study Complete
Location
GSK Investigational Site
San Gabriel, California, United States, 91776
Status
Study Complete
Location
GSK Investigational Site
Warminster, Pennsylvania, United States, 18974
Status
Study Complete
Location
GSK Investigational Site
Tucson, Arizona, United States, 85745
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Aurora, Illinois, United States, 60504
Status
Study Complete
Location
GSK Investigational Site
Edgewater, Florida, United States, 32132
Status
Study Complete
Location
GSK Investigational Site
San Fernando, Pampanga, Philippines, 2000
Status
Study Complete
Location
GSK Investigational Site
Gainesville, Georgia, United States, 30501
Status
Study Complete
Location
GSK Investigational Site
La Plata, Buenos Aires, Argentina, 1900
Status
Study Complete
Location
GSK Investigational Site
Srebrenik, Bosnia and Herzegovina, 75350
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Richmond, Virginia, United States, 23249
Status
Study Complete
Location
GSK Investigational Site
Torrance, California, United States, 90502
Status
Study Complete
Location
GSK Investigational Site
Hartford, Connecticut, United States, 06105
Status
Study Complete
Location
GSK Investigational Site
Sainte Jerome, Québec, Canada, J7Z 5T3
Status
Study Complete
Location
GSK Investigational Site
Hialeah, Florida, United States, 33012
Status
Study Complete
Location
GSK Investigational Site
Landsdale, Pennsylvania, United States, 19446
Status
Study Complete
Location
GSK Investigational Site
Gillespie, Illinois, United States, 62033
Status
Study Complete
Location
GSK Investigational Site
Austell, Georgia, United States, 30106
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Argentina, C1425BEN
Status
Study Complete
Location
GSK Investigational Site
Grand Island, Nebraska, United States, 68803
Status
Study Complete
Location
GSK Investigational Site
Princeton, New Jersey, United States, 08540
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Rancho Mirage, California, United States, 92270
Status
Study Complete
Location
GSK Investigational Site
Melbourne, Florida, United States, 32934
Status
Study Complete
Location
GSK Investigational Site
Neuwied, Rheinland-Pfalz, Germany, 56564
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ingelheim, Rheinland-Pfalz, Germany, 55218
Status
Study Complete
Location
GSK Investigational Site
Brandon, Florida, United States, 33511
Status
Study Complete
Location
GSK Investigational Site
Burien, Washington, United States, 98166
Status
Study Complete
Location
GSK Investigational Site
Banja Luka, Bosnia and Herzegovina, 78000
Status
Study Complete
Location
GSK Investigational Site
Rapid City, South Dakota, United States, 57702
Status
Study Complete
Location
GSK Investigational Site
Stockton, California, United States, 95207
Status
Study Complete
Location
GSK Investigational Site
Vero Beach, Florida, United States, 32960
Status
Study Complete
Location
GSK Investigational Site
Henderson, Nevada, United States, 89014
Status
Study Complete
Location
GSK Investigational Site
Cuernavaca, Morelos, Mexico, 62350
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bucheon-Si, Gyeonggi-Do, South Korea, 420-021
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45355
Status
Study Complete
Location
GSK Investigational Site
Rochester, Michigan, United States, 48307
Status
Study Complete
Location
GSK Investigational Site
Huntersville, North Carolina, United States, 28078
Status
Study Complete
Location
GSK Investigational Site
Bury St Edmunds, Suffolk, United Kingdom, IP30 9QU
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Miami Gardens, Florida, United States, 33169
Status
Study Complete
Location
GSK Investigational Site
Teslić, Bosnia and Herzegovina, 74270
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Freehold, New Jersey, United States, 07728
Status
Study Complete
Location
GSK Investigational Site
Winchester, Virginia, United States, 22601
Status
Study Complete
Location
GSK Investigational Site
Cuautitlan Izcalli, Estado de México, Mexico, 54769
Status
Study Complete
Location
GSK Investigational Site
Orlando, Florida, United States, 32803
Status
Study Complete
Location
GSK Investigational Site
Sacramento, California, United States, 95819
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greensboro, North Carolina, United States, 27403
Status
Study Complete
Location
GSK Investigational Site
Parana, Entre Ríos, Argentina, E3100BHK
Status
Study Complete
Location
GSK Investigational Site
Canet de Mar - Barcelona, Spain, 08360
Status
Study Complete
Location
GSK Investigational Site
Huntington Beach, California, United States, 92647
Status
Study Complete
Location
GSK Investigational Site
Northwood, Middlesex, United Kingdom, HA6 2RN
Status
Study Complete
Location
GSK Investigational Site
Bexhill-on-Sea, United Kingdom, TN40 1JJ
Status
Study Complete
Location
GSK Investigational Site
Easley, South Carolina, United States, 29640
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Daw Park, South Australia, Australia, 5041
Status
Study Complete
Location
GSK Investigational Site
Bronx,, New York, United States, 10457
Status
Study Complete
Location
GSK Investigational Site
Johnston, Rhode Island, United States, 02919
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92111
Status
Study Complete
Location
GSK Investigational Site
Cumming, Georgia, United States, 30041
Status
Study Complete
Location
GSK Investigational Site
Danbury, Connecticut, United States, 06810
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Status
Study Complete
Location
GSK Investigational Site
Duncanville, Texas, United States, 75116
Status
Study Complete
Location
GSK Investigational Site
Rhaunen, Rheinland-Pfalz, Germany, 55624
Status
Study Complete
Location
GSK Investigational Site
Flagstaff, Arizona, United States, 86001
Status
Study Complete
Location
GSK Investigational Site
Vicente López, Buenos Aires, Argentina, 1602
Status
Study Complete
Location
GSK Investigational Site
Aventura, Florida, United States, 33180
Status
Study Complete
Location
GSK Investigational Site
Pensacola, Florida, United States, 32514
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10016
Status
Study Complete
Location
GSK Investigational Site
Miami, Florida, United States, 33185
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Edgbaston, Birmingham, United Kingdom, B15 2SQ
Status
Study Complete
Location
GSK Investigational Site
Trinity, Florida, United States, 34655
Status
Study Complete
Location
GSK Investigational Site
Columbia, South Carolina, United States, 29209
Status
Study Complete
Location
GSK Investigational Site
Chesterfield, Derbyshire, United Kingdom, S40 4AA
Status
Study Complete
Location
GSK Investigational Site
Sacramento, California, United States, 95817
Status
Study Complete
Location
GSK Investigational Site
Youngstown, Ohio, United States, 44501
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ostrava - Poruba, Czech Republic, 70868
Status
Study Complete
Location
GSK Investigational Site
Morelia, Michoacán, Mexico, C.P. 58249
Status
Study Complete
Location
GSK Investigational Site
River Forest, Illinois, United States, 60305
Status
Study Complete
Location
GSK Investigational Site
Long Beach, California, United States, 90822
Status
Study Complete
Location
GSK Investigational Site
Idaho Falls, Idaho, United States, 83402
Status
Study Complete
Location
GSK Investigational Site
L'Hospitalet de Llobregat, Spain, 08907
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140
Status
Study Complete
Location
GSK Investigational Site
Derqui, Pilar, Buenos Aires, Argentina, B1629AHJ
Status
Study Complete
Location
GSK Investigational Site
Pozuelo de Alarcón/Madrid, Spain, 28223
Status
Study Complete
Location
GSK Investigational Site
Corning, New York, United States, 14830
Status
Study Complete
Location
GSK Investigational Site
Peterborough, Cambridgeshire, United Kingdom, PE8 6PL
Status
Study Complete
Location
GSK Investigational Site
Papenburg, Niedersachsen, Germany, 26871
Status
Study Complete
Location
GSK Investigational Site
Deggingen, Baden-Wuerttemberg, Germany, 73326
Status
Study Complete
Location
GSK Investigational Site
Bridgeport, West Virginia, United States, 26330
Status
Study Complete
Location
GSK Investigational Site
Tampa/Florida, Florida, United States, 33607
Status
Study Complete
Location
GSK Investigational Site
Fountain Valley, California, United States, 92708
Status
Study Complete
Location
GSK Investigational Site
Dallas, Texas, United States, 75254
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Pismo Beach, California, United States, 93449
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45231
Status
Study Complete
Location
GSK Investigational Site
Orlando, Florida, United States, 32811
Status
Study Complete
Location
GSK Investigational Site
Cadillac, Michigan, United States, 49601
Status
Study Complete
Location
GSK Investigational Site
Dueren, Nordrhein-Westfalen, Germany, 52349
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Temuco, Región De La Araucania, Chile, 4800798
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60612
Status
Study Complete
Location
GSK Investigational Site
Hayden Lake, Idaho, United States, 83835
Status
Study Complete
Location
GSK Investigational Site
Asheville, North Carolina, United States, 28801
Status
Study Complete
Location
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55116
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Tacoma, Washington, United States, 98405
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45136
Status
Study Complete
Location
GSK Investigational Site
Frankfurt, Baden-Wuerttemberg, Germany, 60596
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97202
Status
Study Complete
Location
GSK Investigational Site
San Martin, Buenos Aires, Argentina, 1650
Status
Study Complete
Location
GSK Investigational Site
Missoula, Montana, United States, 59808
Status
Study Complete
Location
GSK Investigational Site
Toronto, Ontario, Canada, M5T 3A9
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bowling Green, Kentucky, United States, 42101
Status
Study Complete
Location
GSK Investigational Site
Pell City, Alabama, United States, 35128
Status
Study Complete
Location
GSK Investigational Site
Bad Woerrishofen, Bayern, Germany, 86825
Status
Study Complete
Location
GSK Investigational Site
North Miami Beach, Florida, United States, 33179
Status
Study Complete
Location
GSK Investigational Site
Muenchen, Bayern, Germany, 80335
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hollywood, Florida, United States, 33021
Status
Study Complete
Location
GSK Investigational Site
Honolulu, Hawaii, United States, 96813
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
Status
Study Complete
Location
GSK Investigational Site
Huntsville, Texas, United States, 77340
Status
Study Complete
Location
GSK Investigational Site
Fridley, Minnesota, United States, 55432
Status
Study Complete
Location
GSK Investigational Site
Williamston, South Carolina, United States, 29697
Status
Study Complete
Location
GSK Investigational Site
Muncie, Indiana, United States, 47304-5547
Status
Study Complete
Location
GSK Investigational Site
Pergamino, Buenos Aires, Argentina, B2700CPM
Status
Study Complete
Location
GSK Investigational Site
Garden Grove, California, United States, 92844
Status
Study Complete
Location
GSK Investigational Site
Hagerstown, Maryland, United States, 21740
Status
Study Complete
Location
GSK Investigational Site
West Vancouver, British Columbia, Canada, V7T 2Z3
Status
Study Complete
Location
GSK Investigational Site
Morganton, North Carolina, United States, 28655
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15236
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30342
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Opelousas, Louisiana, United States, 70570
Status
Study Complete
Location
GSK Investigational Site
Austin, Texas, United States, 78756
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Clearwater, Florida, United States, 33759
Status
Study Complete
Location
GSK Investigational Site
Centennial, Colorado, United States, 80112
Status
Study Complete
Location
GSK Investigational Site
Buffalo, New York, United States, 14215-1199
Status
Study Complete
Location
GSK Investigational Site
Cerritos, California, United States, 90703
Status
Study Complete
Location
GSK Investigational Site
Elizabeth City, North Carolina, United States, 27909
Status
Study Complete
Location
GSK Investigational Site
Soham, Cambridgeshire, United Kingdom, CB7 5JD
Status
Study Complete
Location
GSK Investigational Site
Great Neck, New York, United States, 11023
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Antonio, Texas, United States, 78215
Status
Study Complete
Location
GSK Investigational Site
Aguascalientes, Aguascalientes, Mexico, 20127
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
Status
Study Complete
Location
GSK Investigational Site
Colorado Springs, Colorado, United States, 80907
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60603
Status
Study Complete
Location
GSK Investigational Site
Fleming Island, Florida, United States, 32003
Status
Study Complete
Location
GSK Investigational Site
Gaffney, South Carolina, United States, 29340
Status
Study Complete
Location
GSK Investigational Site
Belle Vernon, Pennsylvania, United States, 15012
Status
Study Complete
Location
GSK Investigational Site
Foothill Ranch, California, United States, 92610
Status
Study Complete
Location
GSK Investigational Site
St. Petersburg, Florida, United States, 33704
Status
Study Complete
Location
GSK Investigational Site
Skokie, Illinois, United States, 60076
Status
Study Complete
Location
GSK Investigational Site
Bahia Blanca, Buenos Aires, Argentina, B8000FTD
Status
Study Complete
Location
GSK Investigational Site
Thaba Tshwane, Gauteng, South Africa, 0143
Status
Study Complete
Location
GSK Investigational Site
Glendale, Arizona, United States, 85306
Status
Study Complete
Location
GSK Investigational Site
Huntington Park, California, United States, 90255
Status
Study Complete
Location
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44263
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90048
Status
Study Complete
Location
GSK Investigational Site
Detroit, Michigan, United States, 48235
Status
Study Complete
Location
GSK Investigational Site
Albany, New York, United States, 12208
Status
Study Complete
Location
GSK Investigational Site
Lincoln, Nebraska, United States, 68512
Status
Study Complete
Location
GSK Investigational Site
Edison, New Jersey, United States, 8820
Status
Study Complete
Location
GSK Investigational Site
Waterloo, Liverpool, Merseyside, United Kingdom, L22 0LG
Status
Study Complete
Location
GSK Investigational Site
Westfield, New York, United States, 14787
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23219
Status
Study Complete
Location
GSK Investigational Site
Irving, Texas, United States, 75039
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Lodi, New Jersey, United States, 07644
Status
Study Complete
Location
GSK Investigational Site
Manchester, United Kingdom, M15 6SX
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Blue Ridge, Georgia, United States, 30513
Status
Study Complete
Location
GSK Investigational Site
Oxon Hill, Maryland, United States, 20745
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63143
Status
Study Complete
Location
GSK Investigational Site
Pretoria, Gauteng, South Africa, 0183
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hagen, Nordrhein-Westfalen, Germany, 58095
Status
Study Complete
Location
GSK Investigational Site
Lincoln, Nebraska, United States, 68516
Status
Study Complete
Location
GSK Investigational Site
Bruchsal, Baden-Wuerttemberg, Germany, 76646
Status
Study Complete
Location
GSK Investigational Site
Havlickuv brod, Czech Republic, 580 01
Status
Study Complete
Location
GSK Investigational Site
Liverpool, Merseyside, United Kingdom, L9 7AL
Status
Study Complete
Location
GSK Investigational Site
Gainesville, Florida, United States, 32608
Status
Study Complete
Location
GSK Investigational Site
Altamonte Springs, Florida, United States, 32714
Status
Study Complete
Location
GSK Investigational Site
Smithfield, North Carolina, United States, 27577
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Harleysville, Pennsylvania, United States, 19438
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98104
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Evansville, Indiana, United States, 47714
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99208
Status
Study Complete
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30159
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55402
Status
Study Complete
Location
GSK Investigational Site
Syracuse, New York, United States, 13210
Status
Study Complete
Location
GSK Investigational Site
Olivos, Buenos Aires, Argentina, B1605DSX
Status
Study Complete
Location
GSK Investigational Site
Massapequa, New York, United States, 11758
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greensboro, North Carolina, United States, 27408
Status
Study Complete
Location
GSK Investigational Site
Valparaiso, Indiana, United States, 46383
Status
Study Complete
Location
GSK Investigational Site
Boynton Beach, Florida, United States, 33472
Status
Study Complete
Location
GSK Investigational Site
Lansdale, Pennsylvania, United States, 19446
Status
Study Complete
Location
GSK Investigational Site
Banjaluka, Bosnia and Herzegovina, 78000
Status
Study Complete
Location
GSK Investigational Site
Brick, New Jersey, United States, 08723
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Knightdale, North Carolina, United States, 27545
Status
Study Complete
Location
GSK Investigational Site
Bellingham, Washington, United States, 98225
Status
Study Complete
Location
GSK Investigational Site
Kamloops, British Columbia, Canada, V2C 1K7
Status
Study Complete
Location
GSK Investigational Site
Dakota Dunes, South Dakota, United States, 57049
Status
Study Complete
Location
GSK Investigational Site
Gelsenkirchen, Nordrhein-Westfalen, Germany, 45879
Status
Study Complete
Location
GSK Investigational Site
Wellington, Florida, United States, 33414
Status
Study Complete
Location
GSK Investigational Site
Orlando, Florida, United States, 32825
Status
Study Complete
Location
GSK Investigational Site
Marietta, Georgia, United States, 30060
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99207
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Coon Rapids, Minnesota, United States, 55433
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Hollywood, Maryland, United States, 20636
Status
Study Complete
Location
GSK Investigational Site
Pembroke Pines, Florida, United States, 33027
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Mobile, Alabama, United States, 36604
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ruedersdorf, Brandenburg, Germany, 15562
Status
Study Complete
Location
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 51069
Status
Study Complete
Location
GSK Investigational Site
Brooklyn, New York, United States, 11229
Status
Study Complete
Location
GSK Investigational Site
Hazard, Kentucky, United States, 41701
Status
Study Complete
Location
GSK Investigational Site
Goettingen, Niedersachsen, Germany, 37081
Status
Terminated/Withdrawn
Location
GSK Investigational Site
North Chicago, Illinois, United States, 60064
Status
Study Complete
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28210
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21239
Status
Study Complete
Location
GSK Investigational Site
Bedford Park, South Australia, Australia, 5042
Status
Study Complete
Location
GSK Investigational Site
Fayetteville, Tennessee, United States, 37334
Status
Study Complete
Location
GSK Investigational Site
Concepcion del Uruguay, Entre Ríos, Argentina, 3260
Status
Study Complete
Location
GSK Investigational Site
Morningside, Gauteng, South Africa, 2057
Status
Study Complete
Location
GSK Investigational Site
Beaver, Pennsylvania, United States, 15009
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92103
Status
Study Complete
Location
GSK Investigational Site
Florencio Varela, Buenos Aires, Argentina, 1888
Status
Study Complete
Location
GSK Investigational Site
Scranton, Pennsylvania, United States, 18501
Status
Study Complete
Location
GSK Investigational Site
Fayetteville, Arkansas, United States, 72703
Status
Study Complete
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39104
Status
Terminated/Withdrawn
Location
GSK Investigational Site
St. Petersburg, Florida, United States, 33707
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Sierra Vista, Arizona, United States, 85635
Status
Study Complete
Location
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina, B7600FZN
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89119
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10021
Status
Study Complete
Location
GSK Investigational Site
Tyne and Wear, United Kingdom, NE29 8NH
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Greenville, South Carolina, United States, 29615
Status
Study Complete
Location
GSK Investigational Site
Norfolk, Virginia, United States, 23507
Status
Study Complete
Location
GSK Investigational Site
Sarajevo, Bosnia and Herzegovina, 71320
Status
Study Complete
Location
GSK Investigational Site
Monroeville, Pennsylvania, United States, 15146
Status
Study Complete
Location
GSK Investigational Site
Chardon, Ohio, United States, 44024
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Angelo, Texas, United States, 76904
Status
Study Complete
Location
GSK Investigational Site
Lutherville, Maryland, United States, 21093
Status
Study Complete
Location
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19142
Status
Study Complete
Location
GSK Investigational Site
Karlsruhe, Baden-Wuerttemberg, Germany, 76227
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Gold River, California, United States, 95670
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90095
Status
Study Complete
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87108
Status
Study Complete
Location
GSK Investigational Site
Florencio Varela, Argentina, C1073ABA
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Owensboro, Kentucky, United States, 42303-3163
Status
Study Complete
Location
GSK Investigational Site
Santa Monica, California, United States, 90404
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Mission Viejo, California, United States, 92691
Status
Study Complete
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21224
Status
Study Complete
Location
GSK Investigational Site
Solingen, Nordrhein-Westfalen, Germany, 42651
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Los Angeles, California, United States, 90036
Status
Terminated/Withdrawn
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63117
Status
Study Complete
Location
GSK Investigational Site
Summerfield, Florida, United States, 34491
Status
Study Complete
Location
GSK Investigational Site
Crestview Hills, Kentucky, United States, 41017
Status
Study Complete
Location
GSK Investigational Site
New Port Richey, Florida, United States, 34652
Status
Study Complete
Location
GSK Investigational Site
High Point, North Carolina, United States, 27262
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73103
Status
Study Complete
Location
GSK Investigational Site
Phoenixville, Pennsylvania, United States, 19460
Status
Study Complete
Location
GSK Investigational Site
Statesville, North Carolina, United States, 28625
Status
Study Complete
Location
GSK Investigational Site
Quilmes, Buenos Aires, Argentina, B1878FNR
Status
Study Complete
Location
GSK Investigational Site
Kansas City, Missouri, United States, 64106
Status
Study Complete
Location
GSK Investigational Site
Muscle Shoals, Alabama, United States, 35662
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Columbus, Georgia, United States, 31904
Status
Study Complete
Location
GSK Investigational Site
Foehren, Rheinland-Pfalz, Germany, 54343
Status
Study Complete
Location
GSK Investigational Site
Murrells Inlet, South Carolina, United States, 29576
Status
Study Complete
Location
GSK Investigational Site
Viña del Mar, Valparaíso, Chile, 2340000
Status
Study Complete
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
Status
Study Complete
Location
GSK Investigational Site
Royal Oak, Michigan, United States, 48073-6769
Status
Study Complete
Location
GSK Investigational Site
Palm Harbor, Florida, United States, 34684
Status
Study Complete
Location
GSK Investigational Site
Lexington, Kentucky, United States, 40504
Status
Study Complete
Location
GSK Investigational Site
Melrose Park, Illinois, United States, 60160
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Dallas, Texas, United States, 75246
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Fall River, Massachusetts, United States, 02720
Status
Study Complete
Location
GSK Investigational Site
Crystal River, Florida, United States, 34429
Status
Study Complete
Location
GSK Investigational Site
Greensboro, North Carolina, United States, 27401
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Boynton Beach, Florida, United States, 33435
Status
Study Complete
Location
GSK Investigational Site
Sacramento, California, United States, 95816
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Vero Beach, Florida, United States, 32958
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85032
Status
Study Complete
Location
GSK Investigational Site
Hagen, Nordrhein-Westfalen, Germany, 58089
Status
Study Complete
Location
GSK Investigational Site
Visegrad, Bosnia and Herzegovina, 73240
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Franklin, Tennessee, United States, 27064
Status
Study Complete
Location
GSK Investigational Site
Tamarac, Florida, United States, 33319
Status
Study Complete
Location
GSK Investigational Site
Detriot, Michigan, United States, 48201
Status
Terminated/Withdrawn
Location
GSK Investigational Site
West Allis, Wisconsin, United States, 53227
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Palo Alto, California, United States, 94304
Status
Study Complete
Location
GSK Investigational Site
Georgetown, Texas, United States, 78626
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35233
Status
Study Complete
Location
GSK Investigational Site
Port Charlotte, Florida, United States, 33952
Status
Study Complete
Location
GSK Investigational Site
Santa Coloma de Gramenet, Spain, 08921
Status
Study Complete
Location
GSK Investigational Site
Redcliffe, Queensland, Australia, 4020
Status
Study Complete
Location
GSK Investigational Site
Godoy Cruz, Mendoza, Argentina, 5501
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Oxnard, California, United States, 93030-5841
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92117
Status
Study Complete
Location
GSK Investigational Site
Cumberland, Rhode Island, United States, 02864
Status
Study Complete
Location
GSK Investigational Site
Penticton, British Columbia, Canada, V2A 5C8
Status
Study Complete
Location
GSK Investigational Site
Moravsky Krumlov, Czech Republic, 672 01
Status
Study Complete
Location
GSK Investigational Site
Van Nuys, California, United States, 91405
Status
Study Complete
Location
GSK Investigational Site
Istocno Sarajevo, Bosnia and Herzegovina, 71123
Status
Study Complete
Location
GSK Investigational Site
Plymouth, Minnesota, United States, 55441
Status
Study Complete
Location
GSK Investigational Site
Verona, New Jersey, United States, 07044
Status
Study Complete
Location
GSK Investigational Site
Tucson, Arizona, United States, 85710
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Schleswig, Schleswig-Holstein, Germany, 24837
Status
Study Complete
Location
GSK Investigational Site
Woodstock, Georgia, United States, 30189
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32216
Status
Study Complete
Location
GSK Investigational Site
San luis Potosí, San Luis Potosí, Mexico, 78090
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Virginia Beach, Virginia, United States, 23454
Status
Study Complete
Location
GSK Investigational Site
West Covina, California, United States, 91790
Status
Study Complete
Location
GSK Investigational Site
San Miguel de Tucumán, Argentina, 4000
Status
Study Complete
Location
GSK Investigational Site
Port Orange, Florida, United States, 32129
Status
Study Complete
Location
GSK Investigational Site
Maitland, Florida, United States, 32751
Status
Terminated/Withdrawn
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2015-15-07
Actual study completion date
2015-15-07
Plain language summaries
Summary of results in plain language
Available language(s): English
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website